Parissenti AM, Pritzker LB, Dahle MA, Gythfeldt HVL, Masilamani T, Theriault G, St-Onge R, D'costa L, Lingjaerde OC, Haugen MH, Engebraaten O (2025)
High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy
Breast Cancer Res, 27 (1), 143
DOI 10.1186/s13058-025-02092-9, PubMed 40790765

Brodal HP, Pharo H, Vedeld HM, Lind GE (2025)
PoDCall: a robust tool for automated droplet classification in DNA-methylation droplet digital PCR
Mol Oncol (in press)
DOI 10.1002/1878-0261.70105, PubMed 40761129

Radulovic M, Yang C, Stenmark H (2025)
Lysosomal membrane homeostasis and its importance in physiology and disease
Nat Rev Mol Cell Biol (in press)
DOI 10.1038/s41580-025-00873-w, PubMed 40759742

Andersson Y, Løvstakken E, Herud TM, Waagene S, Flatmark K, Fleten KG (2025)
Intraperitoneal Perfusion with Cisplatin or Mitomycin C Improves Survival in Mice Bearing Peritoneal Metastases from Ovarian Cancer
Ann Surg Oncol (in press)
DOI 10.1245/s10434-025-18025-x, PubMed 40788597

Parissenti AM, Pritzker LB, Dahle MA, Gythfeldt HVL, Masilamani T, Theriault G, St-Onge R, D'costa L, Lingjaerde OC, Haugen MH, Engebraaten O (2025)
High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy
Breast Cancer Res, 27 (1), 143
DOI 10.1186/s13058-025-02092-9, PubMed 40790765

Apostol AI, Kotsopoulos J, Gronwald J, Kim RH, Karlan BY, Aeilts A, Cajal TRY, Pal T, Eisen A, Bordeleau L, Foulkes WD, Couch F, Zakalik D, Fruscio R, Sun P, Lubinski J, Tung N, Singer CF, Moller P, Dominguez-Valentin M, Narod SA, Metcalfe K, Hereditary Breast Cancer Clinical Study Group (2025)
Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant
Gynecol Oncol, 201, 44-52 (in press)
DOI 10.1016/j.ygyno.2025.07.030, PubMed 40784323